Dr. Robert Den, Chief Medical Officer of Alpha Tau, added: “The primary endpoints of this trial are feasibility and safety, and on both the data are consistent across all eight patients: every treatment was done as planned, and there have been no unanticipated serious adverse events. The response and survival data are incredibly encouraging for such a difficult disease, and longer follow-up will continue to be of interest in understanding the durability of these responses as we continue to enroll the study.”
Conference Call on Monday, November 16, 2026 at 8:30am ET
Alpha Tau will host a conference call with management, together with Dr. Joshua Palmer, on November 16, 2026, at 8:30 am ET.
To access the call, please register at https://alpha-dart-rgbm-at-sno-26.open-exchange.net/ . An archived webcast will be available on the Company’s website following the event.
From HERE :
https://alphatau.com/alpha-dart-glioblastoma-...-sno-2026/